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Uncertainty Analysis in Intervention
Impact on Health Inequality for
Resource Allocation Decisions
Fan Yang , Ana Duarte , Simon Walker , and Susan Griffin
Cost-effectiveness analysis, routinely used in health care to inform funding decisions, can be extended to consider
impact on health inequality. Distributional cost-effectiveness analysis (DCEA) incorporates socioeconomic differ-
ences in model parameters to capture how an intervention would affect both overall population health and differ-
ences in health between population groups. In DCEA, uncertainty analysis can consider the decision uncertainty
around on both impacts (i.e., the probability that an intervention will increase overall health and the probability that
it will reduce inequality). Using an illustrative example assessing smoking cessation interventions (2 active interven-
tions and a ‘‘no-intervention’’ arm), we demonstrate how the uncertainty analysis could be conducted in DCEA to
inform policy recommendations. We perform value of information (VOI) analysis and analysis of covariance
(ANCOVA) to identify what additional evidence would add most value to the level of confidence in the DCEA
results. The analyses were conducted for both national and local authority-level decisions to explore whether the con-
clusions about decision uncertainty based on the national-level estimates could inform local policy. For the compari-
sons between active interventions and ‘‘no intervention,’’ there was no uncertainty that providing the smoking
cessation intervention would increase overall health but increase inequality. However, there was uncertainty in the
direction of both impacts when comparing between the 2 active interventions. VOI and ANCOVA show that uncer-
tainty in socioeconomic differences in intervention effectiveness and uptake contributes most to the uncertainty in
the DCEA results. This suggests potential value of collecting additional evidence on intervention-related inequalities
for this evaluation. We also found different levels of decision uncertainty between settings, implying that different
types and levels of additional evidence are required for decisions in different localities.
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The value of public health interventions is reflected by
their impacts on overall population health and health
inequality.1,2 Resource allocation decisions in public
health could therefore be informed by distributional
cost-effectiveness analysis (DCEA),3 which extends cost-
effectiveness analysis (CEA) to incorporate health
inequality concerns. DCEA accounts for between-group
differences in the parameters of the evaluation (e.g., the
value of inputs in a decision-analytic model) to estimate
how an intervention affects health in each population
group and then describes its impacts on the overall popu-
lation health and health inequality.
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Uncertainty analysis is an important component of
decision analysis. It reflects the uncertainty in the input
parameters of the decision model and estimates what this
means for the level of confidence in the study results and
for decision uncertainty.4,5 As with any evaluation,
uncertainty in the model parameters of DCEA translates
into uncertainty in the overall results and the decision on
whether an intervention should be introduced.6 The
uncertainty in DCEA would imply the decision uncer-
tainty based on an intervention’s impacts on both overall
health and health inequality (i.e., the probability of cor-
rect conclusions that it will increase overall health and/or
reduce inequality).
Evidence on how the value of model inputs varies
between population groups of interest (e.g., groups with
different socioeconomic status) is a key component in
DCEA. Given concerns about degree and quality of such
evidence, decision makers would be interested to know
whether it is worthwhile obtaining additional evidence to
reduce the uncertainty about intervention impacts and
thus to support decisions to introduce an intervention.
As well as informing whether more evidence is worth-
while in general, it is also important to know on which
model inputs further research would be most valuable.
Questions about the value of further research could be
informed by value of information (VOI) analysis.6
Analysis of covariance (ANCOVA)7 can be used to
explore the correlation between variation in a model
input and variation in the estimated intervention impacts
on overall health and health inequality.
We have previously adapted a DCEA model of smok-
ing cessation interventions to explore how the assessment
of intervention impacts would change when accounting
for socioeconomic variations in model inputs.8 The
model considers the decision in England as a whole and
within 2 local government authorities in England. The 2
local authorities, York and Sheffield, represent popula-
tions of 205,000 and 573,000 individuals, respectively.
They differ in smoking prevalence and population socio-
economic characteristics, with Sheffield having a greater
smoking prevalence overall and greater levels of socioe-
conomic disadvantage compared to York. In England,
the responsibility for many aspects of public health poli-
cies rests with local authorities, yet many published
appraisals of these policies focus only on the national
level. Local decision makers may be interested to know
whether the conclusions about decision uncertainty
based on the national-level estimates could inform local
policy and what additional evidence would add most
value to reduce the decision uncertainty for their area.
In this study, we show how uncertainty analysis can
be employed in DCEA to address the following:
a. What is the uncertainty about whether the interven-
tions increase overall health and/or reduce health
inequality?
b. What is the value of obtaining more information
on how model inputs vary with socioeconomic
characteristics?
c. Among all model inputs incorporating socioeco-
nomic variation, which one contributes most to deci-
sion uncertainty?
d. How generalizable are conclusions about decision
uncertainty and the contribution of different model
inputs to decision uncertainty between settings (i.e.,
England as a whole v. local authority and between
local authorities)?
Methods
An existing DCEA model assessing smoking cessation
interventions was extended to incorporate uncertainty
around the value of model inputs. To do this, model
parameters were characterized as distributions and the
uncertainty then propagated through to the model out-
puts using Monte Carlo simulation (i.e., probabilistic
sensitivity analysis [PSA]).
Model Overview
The model evaluates the costs and health benefits for
adult smokers (18–75 years) from the National Health
Service (NHS) and personal social services perspective
over the individuals’ lifetime.9 Socioeconomic status was
defined by the Index of Multiple Deprivation (IMD), a
weighted composite index combining information from
the 7 domains of deprivation (i.e., income, employment,
health, education, housing, crime, and living environ-
ment) for each small, fixed geographical area of approxi-
mately 1,500 residents in England.10 Using IMD, we can
classify all areas into 5 quintiles, with quintile 1 (IMD1)
denoting the most deprived and quintile 5 (IMD5)
demoting the least deprived. Each person is allocated to
an IMD quintile according to their area of residence.
Two active interventions, varenicline11 and 7.2 mg
e-cigarette,12 were compared to ‘‘no intervention’’ and to
each other. Varenicline is a prescription medication used
to treat nicotine addiction, and e-cigarette is a battery-
operated device that delivers nicotine. Both are accessed
through primary care. Health benefits are expressed as
quality-adjusted life years (QALYs) and costs in pounds
sterling (£, 2018 price year) with an annual discount rate
of 3.5% applied to both benefits and costs, following the
National Institute for Health and Care Excellence
(NICE) guidance.4
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The model is a cohort Markov model, including 3
health states: 1) smokers, 2) former smokers, and 3)
death.13 The full cohort enters the model via the ‘‘smo-
kers’’ health state and is exposed to the mortality and
risk of developing smoking-related diseases. Mortality
differs by age and smoking status, with an age-specific
relative risk of death by smoking status applied to age-
specific all-cause mortality rates. The risk of developing
smoking-related diseases also differs by age and smoking
status. In each annual cycle, smokers have a probability
of quitting smoking (and becoming ‘‘former smokers’’).
Those who receive ‘‘no intervention’’ have a ‘‘back-
ground’’ quit rate of 2% (proportion of current smokers
who naturally quit each year),14 while those who receive
the intervention have a higher quit rate, based on the
original studies reporting the efficiency of the interven-
tions.11,12 Smokers are assumed to receive the interven-
tion in the first year, and intervention costs are applied
in the first cycle. From the second cycle, all smokers have
the background quit rate, and relapse from former smo-
ker to smoker is not modeled (i.e., the relapse rate is
zero). Smokers and former smokers are at risk of 6
smoking-related diseases (modeled as events): lung can-
cer, coronary heart disease, chronic obstructive pulmon-
ary disease, myocardial infarction, stroke, and asthma
exacerbation. Health-related quality of life (HRQoL) in
each state is age and smoking status dependent. Each
smoking-related disease has associated costs and a disuti-
lity (i.e., the decrement in utility due to the impact of the
disease). These diseases are modeled as events that occur
independently. In each cycle, for the hypothetical cohort,
we calculated the number of each disease event that was
then multiplied by the event-related costs and associated
disutility. The costs were added up to estimate the total
costs related to the diseases, and the disutility was com-
bined with health utility to estimate the QALY gained
over the cycle.
Uncertainty in Model Inputs
Socioeconomic variation in model inputs across IMD
quintiles was characterized in the model. A brief sum-
mary is provided below with details reported else-
where.8 Due to a lack of evidence, uncertainty was
assigned to the socioeconomic variation in some model
inputs only.
Socioeconomic variation in smoking prevalence. The
smoking prevalence by IMD quintile, estimated using
Public Health England Local Tobacco Control Profiles
2017 data,15 was assigned independent b distributions to
reflect uncertainty in the PSA (Table 1).
Socioeconomic variation in mortality. The annual mor-
tality rates for smokers were estimated using the general
population all-cause mortality by age and sex according
to IMD quintiles, proportion of smokers, former smo-
kers and nonsmokers, and relative risk of death (see
equation (1) for details).
Annual mortality rate for smokers=
All cause annual mortality rate
(proportion of smokers+ proportion of former smokers
relative risk of death (smokers vs former smokers)
+ proportion of non smokers
relative risk of death (smokers vs non smokers)
ð1Þ
Data on all-cause mortality were extracted from the
Office for National Statistics (ONS) data 2010–2015.16
Data on proportion of smokers, former smokers, and
nonsmokers were estimated previously.9 The relative risk
of death for smokers v. nonsmokers by age group (35–
44, 45–54, 55–64, 65–74, and 75 years) and associated
95% confidence intervals were estimated using mortality
data reported in a UK observational study.17 The study
also provided mortality rates for former smokers to
enable estimates of relative risk of death for smokers v.
former smokers, although this was not stratified by age,
so it was assumed that the relative risk was constant
across age groups. Uncertainty in the estimates of all-
cause mortality and proportions was not available, and
therefore no uncertainty is reflected regarding the under-
lying mortality rate conditioned on IMD. However, the
use of relative risks of death (which are sampled from
lognormal probability distributions) allows us to reflect
some of the uncertainty in these estimates. Details are
presented in Table 1.
Socioeconomic variation in smoking-related diseases.
Socioeconomic variation in smoking-related diseases was
considered in the model by assuming that the average
incidence of smoking-related diseases, reported sepa-
rately for smokers and former smokers,9 was representa-
tive of incidence in IMD3. By applying relative risks of
developing these diseases in other quintiles compared to
IMD3,18 we estimated incidence by IMD quintile.
Although uncertainty was associated with the relative
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Smoking prevalence b (a, b)
IMD1 (most deprived) 17.17% 16.55%, 17.79% 2,441, 11,775 Public Health England
Local Tobacco Control
Profiles 2017 data15
IMD2 15.96% 15.22%, 16.70% 1,516, 7,984
IMD3 14.09% 13.24%, 14.95% 887, 5,406
IMD4 12.68% 11.80%, 13.57% 688, 4,733
IMD5 (least deprived) 11.38% 10.53%, 12.24% 601, 4,676
Relative risk of death Lognormal (lm, lv)
Smokers v. nonsmokers (35–44 years) 1.87 1.34, 2.60 0.63, 0.17 Doll et al.17
Smokers v. nonsmokers (45–54 years) 2.28 1.83, 2.83 0.82, 0.11
Smokers v. nonsmokers (55–64 years) 1.97 1.66, 2.33 0.68, 0.09
Smokers v. nonsmokers (65–74 years) 1.83 1.57, 2.13 0.61, 0.08
Smokers v. nonsmokers (75 years) 1.37 1.18, 1.59 0.31, 0.08
Smokers v. former smokers 1.11 1.04, 1.14 0.09, 0.02
Relative risk of developing smoking-related diseases Lognormal (lm, lv)
IMD1 (most deprived) 1.15 1.06, 1.24 0.137, 0.041 Eberth et al.18
IMD2 1.12 1.03, 1.20 0.109, 0.039
IMD3 1.12 1.04, 1.21 0.114, 0.038
IMD4 1.08 1.00, 1.17 0.079, 0.039
IMD5 (least deprived) 1
Coefficient of HRQoL regression Multivariate normal
Age group (16–24 years) Ref
Age group (25–34 years) –0.0124 Health Survey for England
data sets (2012 and 2014)Age group (35–44 years) –0.0544
Age group (45–54 years) –0.0681
Age group (55–64 years) –0.0986
Age group (65–74 years) –0.107
Age group (75+ years) –0.1630
Former smoker Ref
Smoker –0.0340




IMD5 (least deprived) 0.0736
Constant 0.903
Intervention effectiveness b (a, b)
Natural quit rate 0.02
Quit rate of using varenicline 0.19 6, 25 Chengappa et al.11
Quit rate of using e-cigarette 0.13 13, 87 Caponnetto et al.12
Relative risk of quitting smoking Lognormal (lm, lv)
IMD1 (most deprived) 1 Dobbie et al.20
IMD2 1.35 0.94, 1.81 0.297, 0.168
IMD3 1.22 0.79, 1.73 0.195, 0.201
IMD4 1.27 0.91, 1.67 0.236, 0.154
IMD5 (least deprived) 1.36 0.94, 1.82 0.308, 0.168
Service uptake rate b (a, b)
IMD1 (most deprived) 4.03% 96, 2,284 Love-Koh et al.9
IMD2 6.48% 93, 1,349
IMD3 6.62% 93, 1,316
IMD4 10.14% 90, 795
IMD5 (least deprived) 9.92% 90, 817
HRQoL, health-related quality of life; IMD, Index of Multiple Deprivation; lm, mean of the log-transformed value; lv, standard deviation of the
log-transformed value.
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risks (Table 1), a variance-covariance matrix for the
regression model was not reported to allow for correla-
tion across these parameters. Therefore, independent
lognormal distributions were assigned to the log value of
each of the relative risks as a second-best alternative to
capturing uncertainty in these inputs.
Socioeconomic variation in HRQoL. Results from a lin-
ear regression model using EQ-5D-3L data from the
Health Survey for England data sets19 were used to esti-
mate socioeconomic variation in HRQoL. The variance-
covariance matrix was extracted, and the corresponding
Cholesky decomposition was used to obtain correlated
draws from a multivariate normal distribution for use in
the PSA. The regression coefficients were applied in the
DCEA to estimate HRQoL values disaggregated by
smoking status, age, and IMD quintiles (Table 1).
Socioeconomic variation in intervention effectiveness. As
there was no information on socioeconomic status in the
original studies reporting the 12-month quit rates of the
interventions,11,12 we assumed these were the average
effect that could represent that of IMD3 and then used
the relative risks of quitting smoking by IMD20 to esti-
mate the socioeconomic variation in intervention effec-
tiveness. These relative risks also applied to the no-
intervention arm. We assigned b distributions to the
average quit rates of the interventions and independent
lognormal distributions to the log value of each of the
relative risks to reflect uncertainty for the PSA (see
Table 1 for details).
Socioeconomic variation in intervention uptake. As there
were no data on the uncertainty surrounding the esti-
mates about the uptake rate of NHS Stop Smoking
Service by IMD,9 we assumed a standard error of 10%
of mean value and independent b distributions in the
PSA (Table 1).
Others. Other model inputs for which we considered
uncertainty but not socioeconomic variation are dis-
played in Supplemental Table S1, including costs of
interventions, costs of smoking-related diseases, and dis-
utility due to smoking-related diseases. We assumed that
a given smoking-related disease event would incur the
same costs regardless of IMD. To reflect the uncertainty,
we assumed the standard error was equal to 10% of
mean value and assigned gamma distributions. The disu-
tility due to each disease event was applied as absolute
decrements to the baseline HRQoL estimates. Mean
estimates and standard errors for disutility were
extracted from several studies21–24 (see Suppl. Table S1
for details), and gamma distributions were assigned to
reflect the uncertainty in the PSA.
Outcomes of Interest
Our outcomes of interest from the DCEA model were
the impact on overall health, measured using population
incremental net health benefit (iNHB), and the impact on
health inequality, measured using the difference between
population incremental ‘‘equally distributed equivalent’’
health (EDE) and population iNHB. Our base popula-
tion size was 42,994,944 (all adults in England) based on
ONS midyear population estimates for 2017.25
Population iNHB. For each IMD quintile, the model
estimates the incremental costs and incremental direct
health benefits of providing the active interventions com-
pared to no intervention. If an intervention is implemen-
ted that requires additional resources, there would be
forgone health associated with not using that funding for
other health-improving services (i.e., health opportunity
costs). To capture the impact of the intervention on each
IMD quintile, the distribution of the health opportunity
costs also needs to be considered. As a marginal increase
in the NHS budget is expected to be spent more on treat-
ing deprived groups, the health opportunity costs of
increased spending on other activities fall more heavily
on the more deprived.26 Using the lower bound of the
NICE cost-effectiveness threshold of £20,00027 and the
proportion of the health opportunity costs borne by each
IMD,26 incremental costs are converted to the health
opportunity costs by IMD and then subtracted from the
incremental direct health benefits to obtain the iNHB for
each IMD quintile. The impact on overall health is the
sum of the iNHB across all quintiles. An intervention
with a positive population iNHB is considered to
improve overall health.
Population incremental EDE. The value of the distribu-
tion of health across IMD quintiles can be described
using 1 measure, EDE health. We derive EDE health
using an Atkinson index,28 for which we inform
the inequality aversion parameter based on the strength
of the general public’s preference toward reducing
health inequality, elicited from a population survey in
England.29 Bellù and Liberati30 provide a step-by-step
tutorial to calculating the Atkinson index and the EDE
for the distribution of income, and we apply that process
to the distribution of health. EDE health adjusts the
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value of overall population health according to the level
of inequality in its distribution and the level of inequality
aversion. We calculate EDE health with ‘‘no interven-
tion’’ using evidence on the baseline distribution of
health measured using quality-adjusted life expectancy
(QALE).31 (QALE is a measure of life expectancy that is
weighted by the health-related quality of life; i.e., it rep-
resents the number of QALYs an individual is expected
to experience over their lifetime from birth.) For the 2
active interventions, we add the iNHB for each IMD
quintile to the corresponding baseline QALE in that
quintile. This provides the predicted distribution of
health following the implementation of the interventions,
which can also be summarized by the EDE health. By
subtracting the baseline EDE health from the EDE
health with the intervention, we calculate the change in
population EDE health due to the provision of active
intervention (i.e., population incremental EDE [iEDE]).
A positive change in EDE could be the result of an
increase in overall health, a reduction in health inequal-
ity, or both. To isolate the impact on health inequality,
the difference between iEDE and iNHB is used. An
intervention with a positive difference (iEDE-iNHB .0;
i.e., iEDE . iNHB) is considered to have reduced health
inequality.
We can also calculate the same metrics for the com-
parison between the 2 active interventions. Detailed
information on the calculation of iNHB and iEDE is
available in a separate publication.8
Uncertainty Analysis
PSA was performed using Monte Carlo simulation
(1,000 simulations). For each simulation, population-
level iNHB and (iEDE-iNHB) were estimated for all the
pairwise comparisons. The uncertainty in the results was
evaluated using the probability of increasing overall
health (iNHB .0) and the probability of reducing health
inequality (iEDE . iNHB). Results were presented
visually as scatterplots on the ‘‘health equity impact
plane.’’32 This plane illustrates impacts on overall health
and inequality simultaneously, with the y-axis indicating
the impact on overall health (here population iNHB)
and the x-axis indicating the impact on health inequality
(here the difference between population iEDE and popu-
lation iNHB). An intervention that improves overall
health (iNHB .0) falls in the upper side of the plane. An
intervention that reduces inequality (iEDE . iNHB)
falls in the right side of the plane.
The contribution of uncertainty in each group of
associated model inputs was assessed using 2 methods:
VOI analysis via the Sheffield Accelerated Value of
Information (SAVI) platform33 and analysis of covar-
iance (ANCOVA).7 VOI can be conducted including
expected value of perfect information (EVPI) and
expected value of partial perfect information (EVPPI)6
to estimate the monetary value of resolving all of the
decision uncertainty related to all parameters (EVPI) or
a subset of parameters (EVPPI).34 In this study, EVPI
and EVPPI for the total population were calculated.
ANCOVA captures the relative effect of the variation in
model inputs to the variation in the results by fitting a
general linear regression model.7 It is expected that para-
meters that explain most variation in model outputs
would also be the ones that contribute most to decision
uncertainty. The 1,000 sets of input values and corre-
sponding outcomes from the Monte Carlo simulations
were recorded for input into SAVI to undertake VOI
and to facilitate linear regression for ANCOVA. For
VOI, the overall EVPI and EVPPI for each subset of
parameters were reported, and for ANCOVA, the pro-
portion of sum of squares explained by variation in input
parameters was reported, both with a higher value indi-
cating more importance for determining uncertainty/var-
iation in outputs.
Local Authority-Level Analysis
The analysis was also conducted for 2 local authorities
(York and Sheffield) considering the differences in smok-
ing prevalence and associated uncertainty15 (Table 2), the
different population sizes (York: 207,000 and Sheffield:
574,000), and distributions of socioeconomic groups35
(Figure 1). Uncertainty in the other model inputs was
based on those for England in the absence of relevant
data at the local level.
Results
Base Case
The base case results at the national level are presented
in Table 3. Compared to no intervention, both active
interventions were estimated to improve overall health
(iNHB: 123,749 QALYs [varenicline]; 80,782 QALYs
[e-cigarette]) but increase health inequality (iEDE-iNHB:
–17,196 QALYs [varenicline]; –10,780 [e-cigarette]).
Compared to e-cigarette, varenicline was estimated to
increase overall health (iNHB: 42,968 QALYs) but
increase health inequality (iEDE-iNHB: –6,417 QALYs).
Uncertainty Analysis
PSA results are presented in Table 3 and Figure 2.
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For the comparisons between active interventions and
no intervention, the probability of improvement in over-
all health (iNHB .0) was 100%, and the probability of
reduction in health inequality (iEDE . iNHB) was 0%
(Table 3), suggesting no uncertainty around the conclu-
sion that provision of varenicline or e-cigarette would
increase overall health but increase inequality (Figure
2a,b). VOI analysis was not performed as there was no
decision uncertainty. ANCOVA results showed that the
variation in overall health impact was mainly explained
by the variations in the intervention average quit rate
and in the relative risks of quitting smoking between
socioeconomic groups; the variation in health inequality
impact was explained by these and also by the variation
in the intervention uptake rates between groups (Figure
3a,b).
Table 2 Smoking Prevalence at Local Authority
Characteristic Mean, % 95% Confidence Interval, % Reference
York
IMD1 (most deprived) 16.91 11.86, 21.96 Public Health England Local Tobacco Control
Profiles 2017 data15IMD2 14.56 9.95, 19.16
IMD3 13.57 9.19, 17.96
IMD4 11.64 7.62, 15.66
IMD5 (least deprived) 10.78 6.95, 14.60
Sheffield
IMD1 (most deprived) 22.27 15.86, 28.68 Public Health England Local Tobacco Control
Profiles 2017 data15IMD2 20.60 14.47, 26.72
IMD3 19.84 13.89, 25.79
IMD4 18.45 12.74, 24.16
IMD5 (least deprived) 17.74 12.21, 23.28
IMD, Index of Multiple Deprivation.
Figure 1 Population distribution according to Index of
Multiple Deprivation (IMD) in York and Sheffield.
Table 3 Estimates of Intervention Impacts
Region Intervention
Impact on Overall Health Impact on Health Inequality
Probability (%) of
(iNHB, QALYs) (iEDE-iNHB, QALYs) iNHB .0 iEDE . iNHB
England Varenicline v. no intervention 123,749 –17,196 100.00 0.00
E-cigarette v. no intervention 80,782 –10,780 100.00 0.00
Varenicline v. e-cigarette 42,968 –6,417 76.20 19.40
York Varenicline v. no intervention 659 –9 100.00 38.70
E-cigarette v. no intervention 431 3 100.00 57.90
Varenicline v. e-cigarette 229 –11 76.00 20.40
Sheffield Varenicline v. no intervention 2,092 –467 100.00 0.00
E-cigarette v. no intervention 1,365 –303 100.00 0.00
Varenicline v. e-cigarette 727 –164 76.20 22.20
iEDE, incremental equally distributed equivalent health; iNHB, incremental net health benefit; QALY, quality-adjusted life year.
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For the comparison between varenicline and e-cigar-
ette, there was uncertainty as to whether varenicline
increases overall health (probability of 76.20%) and
reduces health inequality (probability of 19.40%) com-
pared to e-cigarette (Table 3). The overall population
EVPI for the impact on overall health and for the impact
on health inequality, estimated by VOI analysis, was
£136,312,000 and £12,847,000, respectively. The £136
million demotes the value of eliminating all uncertainty
from the analysis about which active intervention
improves overall health, and the £12 million denotes the
value of eliminating all uncertainty about which active
intervention reduces health inequality (Suppl. Table S2).
Figure 4 presents the EVPPI results that the uncertainty
in both impacts was mainly determined by the uncer-
tainty in the average quit rate of varenicline and in the
average quit rate of e-cigarette. None of the uncertainty
in socioeconomic pattern of parameters appears to con-
tribute to the uncertainty in the results of the comparison
between the 2 active interventions. The results from the
ANCOVA (Figure 3c) are similar.
Local Authority
Table 3 also presents the base case and PSA results for
York and Sheffield. Compared to no intervention, both
active interventions were estimated to increase overall
health, and there was no uncertainty around this conclu-
sion. However, for the impact on health inequality, the
conclusion about whether the intervention increases/
reduces inequality differed, and there were different lev-
els of uncertainty around it between settings (Table 3
and Figure 5). In York, varenicline was estimated to
increase inequality with the probability of being inequal-
ity reducing at 38.70%, compared to no intervention,
while e-cigarette was estimated to reduce health inequal-
ity with the probability of being inequality reducing at
57.90%. In Sheffield, both active interventions were esti-
mated to increase overall health and increase inequality
with no uncertainty.
For the comparison between varenicline and e-cigar-
ette, there was uncertainty as to whether varenicline
increases overall health (76.00% in York and 76.20%
in Sheffield) and reduces health inequality (20.40% in
York and 22.20% in Sheffield) compared to e-cigarette
(Table 3).
ANCOVA and VOI results showed consistent results
as that observed for England, with the exception that the
uncertainty in smoking prevalence also contributed to
the uncertainty about reduction in inequality of active
interventions compared to no intervention at the local
authority level (Suppl. Figures S1–S4). In York, the
uncertainty in smoking prevalence also explained the
uncertainty in inequality impact of varenicline compared
to e-cigarette (Suppl. Figures S1 and S3). Overall EVPI
and EVPPI estimates for both local authorities are avail-
able in Supplemental Tables S3 to S5.
Discussion
In this study, we demonstrate for the first time how
uncertainty analysis can be employed when assessing an
intervention’s impacts on both overall population health
and health inequality. The probability of the inter-
vention being health-improving and the probability
of being health inequality-reducing were estimated, to
Figure 2 Scatterplots on equity impact plane for all adults in England (n = 42,994,944). iEDE, incremental equally distributed
equivalent health; iNHB, incremental net health benefit.
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Figure 3 Analysis of covariance (ANCOVA) results. HRQoL, health-related quality of life; IMD, Index of Multiple Deprivation.
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Figure 4 Expected value of partial perfect information (EVPPI) results of comparison between varenicline and e-cigarette.
HRQoL, health-related quality of life; IMD, Index of Multiple Deprivation.
Figure 5 Scatterplots on equity impact plane in York and Sheffield. iEDE, incremental equally distributed equivalent health;
iNHB, incremental net health benefit. *The population sizes are rough approximation, rounded to the nearest thousand.
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characterize the level of confidence in the qualitative con-
clusions about the intervention impacts (increase/reduce
population health and reduce/increase inequality). The
analysis we performed here provides guidance for future
studies to apply uncertainty analysis in DCEAs. As
socioeconomic variation in model inputs was found to
affect the DCEA model outputs,8 this study furthers our
understanding by exploring how and to what extent the
uncertainty in socioeconomic variation in model inputs
can translate into uncertainty in the estimated interven-
tion impacts.
We found no uncertainty surrounding the conclusion
that provision of smoking cessation interventions, vareni-
cline or e-cigarette, is likely to improve overall health and
increase health inequality in England. The variation in
the estimated impacts was mainly explained by the varia-
tion in the average quit rate of the intervention and the
variations in the socioeconomic pattern of intervention-
related characteristics, that is, how population groups
differ in the probability of quitting smoking and how
they differ in the intervention uptake rate. Among all
model inputs incorporating socioeconomic variation, the
uncertainty in intervention-related variations seems to
contribute most to the decision uncertainty. This finding
would direct efforts to focus limited resources to collect
further evidence on these variations to support decision
making. It should be noted that the influence of interven-
tion uptake rates on variation of health inequality impact
(measured using iEDE-iNHB) was higher than that on
variation of overall health impact (measured using
iNHB) (Figure 3). This may be because iEDE incorpo-
rates inequality while iNHB does not. Increasing uptake
in any group will increase iNHB. Increasing uptake of
the more deprived will increase iEDE to a greater extent,
resulting in less inequality (positive change in [iEDE-
iNHB]), while increasing uptake of the less deprived will
increase iEDE to a lesser extent, resulting in more
inequality (negative change in [iEDE-iNHB]). This
means when intervention uptake rates vary, how the
overall health impact would change can be predicted by
the direction in which the rates vary (increase/decrease),
but how the health inequality impact would change
depends on in what direction and in which groups (more
deprived/less deprived).
For the comparison between the 2 interventions,
which share the same socioeconomic pattern in model
inputs, uncertainty exists as to which one would improve
overall health and reduce inequality. The value of infor-
mation analysis suggested that there may be value in
research that could eliminate these uncertainties.
Currently, EVPI for the inequality impact from a DCEA
has not been formally used in decision making. The
population EVPI value for further research that elimi-
nated uncertainty as to which active intervention reduced
health inequality impact was about £12 million. In our
example, this denotes the cost of uncertainty about
whether the improvement in health measured in EDE
QALYs exceeds the improvement in overall health. A
decision maker with a strong inequality focus would
potentially be interested in this if they would like to be
certain that the welfare improvement (measured using
iEDE) was worth at least as much if not more than the
health improvement (measured using iNHB). It is the
upper bound to the value of research to ensure that an
intervention is inequality reducing and to avoid the con-
sequences of inadvertently recommending one that is
inequality increasing.
When local authority level evidence was considered,
the level of uncertainty differed greatly between national
and local levels and between the 2 local authorities for
the same comparisons. The uncertainty in smoking pre-
valence was larger at the local level (Table 2) compared
to the national figures (Table 1), so it may have been
expected that this would have translated into more
uncertainty in inequality impact at the local level.
However, in Sheffield, there was no uncertainty that pro-
viding smoking cessation services is likely to increase
inequality. This discrepancy may be explained by the
area-specific characteristics used in the model, smoking
prevalence (Table 2) and population deprivation struc-
ture (Figure 1). For a given individual smoker, smoking
cessation is expected to have less success in helping that
smoker to quit as the deprivation of the local area
increases (Table 1). However, the services still offer an
expected improvement in health to all individuals that
use them (Suppl. Table S6). Successful quit attempts
translate into cost savings for the NHS. Smoking cessa-
tion produces fewer additional successful quit attempts
per smoker in deprived areas, and therefore such services
are less likely to realize cost savings from individual smo-
kers in more deprived areas (Suppl. Table S6). Previous
research indicates that cost savings would benefit more
deprived areas to the greatest degree.26 Thus, smoking
cessation is inequality increasing in the distribution of
direct health benefits of quitting smoking and inequality
reducing in the health benefits from cost saving per smo-
ker. The balance of health gains from smoking cessation
services depends on the proportion of the population in
each IMD quintile (which can depart from 20% at local
level) and the smoking prevalence among residents in
each IMD quintile. When estimating the impact at the
local authority level, differences in smoking prevalence
and population deprivation structure affect the results.
To illustrate it, we explored some scenarios (Suppl. Table
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S7). At the national level, per 100,000 population, the
inequality impact (iEDE-iNHB) with varenicline is –40
QALYs. Changing the smoking prevalence in each IMD
quintile to that observed in each local area (scenario a)
results in a similar change in iEDE-iNHB using York
patterns of smoking (–37 QALYs) but a greater discre-
pancy using Sheffield smoking prevalence (–70 QALYs).
Maintaining national smoking rates in each IMD quin-
tile but using each local area population distribution
across IMD quintiles (scenario b) would show minimal
impact on inequality using the York population structure
(–4 QALYs) and a slightly higher impact on inequality
compared to the national level using the Sheffield popu-
lation structure (–50 QALYs). This indicates that in
York, the less disadvantaged population structure
explains most of the difference, while in Sheffield, both
population structure and smoking prevalence explain the
difference, but smoking prevalence to the greater degree.
Compared to the national-level estimates, local area char-
acteristics imply that providing smoking cessation services
is not expected to increase inequality in York but could
increase it by a greater degree in Sheffield. Therefore, the
inequality impact of the smoking cessation services differs
between York and Sheffield. Altogether this implies that
estimates of intervention impact on inequality should not
be generalized between settings and that setting-specific
uncertainty level in model inputs should be considered in
DCEAs to inform local decision makers.
We note the limitations of this study. First, although
we performed the DCEA at both national and local lev-
els, only local information on smoking prevalence and
population distribution was considered. Thus, most of
the remaining model inputs with socioeconomic varia-
tion were still based on the national figures. As smoking
prevalence was found to considerably affect the uncer-
tainty in results, other local-level model inputs may also
affect the decision uncertainty to some extent. Further
analysis should seek to incorporate more local-level evi-
dence to explore such effect in more detail. Second, the
uncertainty surrounding the distribution of health oppor-
tunity costs was absent and thus not included in the anal-
ysis. It is an important parameter in the calculation of
EDE health, so it may have considerable impact on the
uncertainty around the intervention’s impact on inequal-
ity. Third, when defining the socioeconomic pattern in
model inputs, we modeled uncertainty in some between-
group differences as independent due to the unavailabil-
ity of data. For example, we assigned independent distri-
butions to the smoking prevalence across IMD quintiles.
Alternative specifications would be worth considering,
including those that reflect correlation and dependency,
and the possibility of summarizing the socioeconomic
pattern with one single parameter. Last, the conclusion
that uncertainty in intervention-related socioeconomic
variations would drive the uncertainty in estimated inter-
vention impacts was drawn from this single case study
only. The model may omit other important socioeco-
nomic differences. For example, socioeconomic variation
in relapse rate was not considered. Evidence from South
Korea suggests that relapse may be higher in more
deprived groups,36 which would make the interventions
even less effective in the more deprived groups and lead
to less favorable results in terms of the potential for the
smoking cessation services to reduce inequalities. In the
comparison between the 2 active interventions, we used
the same socioeconomic pattern in uptake, but there is
some evidence that variation in intervention uptake is
associated with the type of intervention.9 Future applica-
tions of the uncertainty analysis in more DCEAs would
add to our results to advance our understanding of what
uncertainty drives the uncertain conclusions about the
intervention impacts. The method we present here for
analyzing and presenting the results would still apply.
Conclusions
Using a DCEA of smoking cessation interventions, our
analysis demonstrates that uncertainty analysis within
DCEA is feasible and requires little data beyond the
requirements of the main analysis. Furthermore, it pro-
vides additional information on the confidence level of
the conclusions to support decision making. This study
found that uncertainty in intervention-related socioeco-
nomic variation would contribute most to the uncertainty
in the DCEA results, suggesting potential value of evi-
dence on intervention-related inequality in assessing pub-
lic health interventions. Our analysis also demonstrates
differences in decision uncertainty between settings, sug-
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